INGN-241

N/A

Report date: 2023/10/26 16:40:27

Base Information

Drug NameINGN-241

Drug Alias NameAd-mda7Mda 7 gene therapy - IntrogenAdenoviral-mda7 - IntrogenINGN-241

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsVascular endothelial growth factor inhibitorsNuclear factor NF-kappa-B complex inhibitors

TargetsNuclear factor NF-kappa-B complexVascular endothelial growth factorEpidermal growth factor receptor erbB1

Therapy Area/IndicationsLung NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesColumbia University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIntrogen Glaxosmithkline Plc Columbia University

Active IndicationsN/A

Inactive IndicationsLung NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[5]

Other Information

ATC CodeN/A